ACS study defines lost earnings for black cancer patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A new American Cancer Society study puts a price tag on racial disparities in cancer mortality, finding that $3.2 billion in lost earnings would have been avoided in 2015 if non-Hispanic blacks had equal years of life lost from cancer deaths and earning rates as NH whites.

The study appears in JNCI Cancer Spectrum.

Investigators, led by Jingxuan Zhao, compared person-years of life lost and lost earnings due to premature cancer deaths by race/ethnicity. PYLL was calculated using national cancer death and life expectancy data. That was combined with annual median earnings to generate lost earnings. PYLL and lost earnings were then compared among individuals who died at age 16-84 years due to cancer by racial/ethnic groups: NH white, NH black, NH Asian or Pacific Islander, and Hispanic.

They found that in 2015, age-standardized lost earning rates (per 100,000 person-years) were $34.9 million for NH whites, $43.5 million for NH blacks, $22.2 million for APIs, and $24.5 million for Hispanics. NH blacks had higher age-standardized PYLL and lost earning rates than NH whites for 13 out of 19 cancer sites studied.

“If age-specific PYLL and lost earning rates for NH blacks were the same as those of NH whites, 241,334 PYLLs and $3.2 billion lost earnings (22.6% of the total lost earnings among NH blacks) would have been avoided,” the authors write. “Improving equal access to effective cancer prevention, screening, and treatment will be important in reducing the disproportional economic burden associated with racial/ethnic disparities,” they conclude.

Table of Contents

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login